U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
The U.S. Food and Drug Administration has granted approval for a breakthrough pancreatic cancer treatment that clinical trials show significantly extends patient survival. The decision represents a major advancement in addressing one of the most difficult-to-treat cancers.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Excellent (80/100)Sources
US drug agency approves breakthrough treatment for pancreatic cancer
Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.
Read full article →New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many
Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more.
By Rebecca Robbins and Carolyn Y. Johnson
Read full article →FDA approves breakthrough pancreatic cancer drug
The FDA has approved a new drug to treat pancreatic cancer. NPR's A Martinez speaks with Adam Feuerstein, who writes for the science and health website STAT.
By A Martínez
Read full article →U.S. FDA approves landmark pancreatic cancer drug
Revolution’s daraxonrasib pill blocks a mutated protein that fuels tumour growth in more than 90% of pancreatic cancer cases
By Matthew Perrone And Lauran Neergaard
Read full article →Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit - Taiwan News
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit Taiwan News
Read full article →US drug agency approves breakthrough treatment for pancreatic cancer
The US Food and Drug Administration has approved a treatment for pancreatic cancer that, in clinical trials, nearly doubled the overall survival time for patients.
By Abubakar Ibrahim
Read full article →
